BriaCell’s Subsidiary, BriaPro, Files Patent Application for Immuno-Oncology Platform with Novel Multitargeting Agents
BriaCell Therapeutics (NASDAQ: BCTX) and its subsidiary BriaPro have announced the filing of a patent application for their novel TILsRx immunotherapy platform. The platform is designed to develop multivalent agents that can simultaneously target multiple cancer-associated and immune pathway targets.
The technology focuses on activating tumor-infiltrating lymphocytes (TILs) and includes key components such as soluble CD80, anti-CD3, IL-21, and anti-STEAP1. An early candidate target is B7-H3, which is overexpressed in multiple cancers including prostate, lung, breast, pancreatic, and ovarian cancer.
The platform aims to provide improved clinical responses while minimizing off-target toxicity, with the flexibility to incorporate new immunotherapy targets as they are identified.
BriaCell Therapeutics (NASDAQ: BCTX) e la sua controllata BriaPro hanno annunciato la presentazione di una domanda di brevetto per la loro innovativa piattaforma di immunoterapia TILsRx. Questa piattaforma è progettata per sviluppare agenti multivalenti in grado di colpire simultaneamente molteplici bersagli associati al cancro e alle vie immunitarie.
La tecnologia si concentra sull'attivazione dei linfociti infiltranti il tumore (TILs) e comprende componenti chiave come CD80 solubile, anti-CD3, IL-21 e anti-STEAP1. Un primo bersaglio candidato è B7-H3, una proteina sovraespressa in diversi tipi di cancro, tra cui prostata, polmone, seno, pancreas e ovaio.
La piattaforma punta a offrire risposte cliniche migliorate riducendo al minimo la tossicità fuori bersaglio, mantenendo la flessibilità di integrare nuovi bersagli immunoterapici man mano che vengono scoperti.
BriaCell Therapeutics (NASDAQ: BCTX) y su subsidiaria BriaPro han anunciado la presentación de una solicitud de patente para su novedosa plataforma de inmunoterapia TILsRx. Esta plataforma está diseñada para desarrollar agentes multivalentes que puedan dirigirse simultáneamente a múltiples objetivos asociados con el cáncer y las vías inmunitarias.
La tecnología se centra en activar los linfocitos infiltrantes de tumores (TILs) e incluye componentes clave como CD80 soluble, anti-CD3, IL-21 y anti-STEAP1. Un objetivo candidato inicial es B7-H3, que está sobreexpresado en varios tipos de cáncer, incluyendo próstata, pulmón, mama, páncreas y ovario.
La plataforma busca proporcionar respuestas clínicas mejoradas mientras minimiza la toxicidad fuera del objetivo, con la flexibilidad de incorporar nuevos objetivos de inmunoterapia a medida que se identifican.
BriaCell Therapeutics (NASDAQ: BCTX)와 자회사 BriaPro가 새로운 TILsRx 면역치료 플랫폼에 대한 특허 출원을 발표했습니다. 이 플랫폼은 여러 암 관련 및 면역 경로 표적을 동시에 겨냥할 수 있는 다가성 제제를 개발하도록 설계되었습니다.
이 기술은 종양 침윤 림프구(TILs)를 활성화하는 데 중점을 두고 있으며, 가용성 CD80, anti-CD3, IL-21, anti-STEAP1과 같은 핵심 요소를 포함합니다. 초기 후보 표적으로는 전립선암, 폐암, 유방암, 췌장암, 난소암 등 여러 암에서 과발현되는 B7-H3가 있습니다.
이 플랫폼은 표적 외 독성을 최소화하면서 임상 반응을 개선하고, 새로운 면역치료 표적이 확인될 때마다 유연하게 통합할 수 있도록 설계되었습니다.
BriaCell Therapeutics (NASDAQ : BCTX) et sa filiale BriaPro ont annoncé le dépôt d'une demande de brevet pour leur nouvelle plateforme d'immunothérapie TILsRx. Cette plateforme est conçue pour développer des agents multivalents capables de cibler simultanément plusieurs cibles associées au cancer et aux voies immunitaires.
La technologie se concentre sur l'activation des lymphocytes infiltrant la tumeur (TILs) et comprend des composants clés tels que CD80 soluble, anti-CD3, IL-21 et anti-STEAP1. Une cible candidate précoce est B7-H3, qui est surexprimée dans plusieurs cancers, notamment de la prostate, du poumon, du sein, du pancréas et de l'ovaire.
La plateforme vise à offrir des réponses cliniques améliorées tout en minimisant la toxicité hors cible, avec la flexibilité d'intégrer de nouvelles cibles d'immunothérapie au fur et à mesure de leur identification.
BriaCell Therapeutics (NASDAQ: BCTX) und seine Tochtergesellschaft BriaPro haben die Einreichung einer Patentanmeldung für ihre neuartige TILsRx-Immuntherapie-Plattform bekannt gegeben. Die Plattform ist darauf ausgelegt, multivalente Wirkstoffe zu entwickeln, die gleichzeitig mehrere krebsassoziierte und immunologische Zielstrukturen ansprechen können.
Die Technologie konzentriert sich auf die Aktivierung tumorinfiltrierender Lymphozyten (TILs) und umfasst wichtige Komponenten wie lösliches CD80, Anti-CD3, IL-21 und Anti-STEAP1. Ein erster Kandidat als Zielstruktur ist B7-H3, das in verschiedenen Krebsarten wie Prostata-, Lungen-, Brust-, Pankreas- und Eierstockkrebs überexprimiert wird.
Die Plattform zielt darauf ab, verbesserte klinische Reaktionen zu ermöglichen und gleichzeitig die Off-Target-Toxizität zu minimieren, mit der Flexibilität, neue immuntherapeutische Ziele zu integrieren, sobald diese identifiziert werden.
- Novel multivalent technology enables targeting multiple cancer pathways simultaneously
- Platform designed for selective cancer cell targeting with improved safety profile
- Technology applicable to multiple cancer types including prostate, lung, breast, pancreatic, and ovarian cancers
- Cost-effective manufacturing process with flexible design for future target incorporation
- Platform is in early development stages with no clinical validation yet
- Patent application is provisional and not yet granted
Insights
BriaCell's subsidiary filed a patent for a novel multi-targeting cancer platform that could overcome immune suppression with potential applications across multiple cancer types.
BriaCell's subsidiary BriaPro has filed a provisional patent application for a new immuno-oncology platform called TILsRx. This platform represents a significant technological development in cancer immunotherapy by enabling simultaneous targeting of multiple cancer-associated and immune pathway targets.
The technology addresses a key challenge in cancer immunotherapy: T cell exhaustion and immune suppression in the tumor microenvironment. Current immunotherapies often face limitations because cancer cells can suppress immune responses, making treatments less effective over time. The TILsRx platform aims to overcome this by activating tumor-infiltrating lymphocytes (TILs) while enhancing their binding to tumor cells and blocking immune checkpoints that suppress anti-tumor responses.
What makes this platform particularly noteworthy is its multivalent approach, incorporating several functional components in a single agent. These include soluble CD80 (which serves as both checkpoint inhibitor and immunostimulator), anti-CD3 (a T cell activator), IL-21 (enhances cytotoxic T cell function), and targeting elements like anti-STEAP1 for cancer specificity. An early focus is on B7-H3, an antigen overexpressed in multiple cancer types including prostate, lung, breast, pancreatic, and ovarian cancers.
The platform's modular design allows for efficient manufacturing while maintaining flexibility to incorporate new targets. This could enable faster development of multiple cancer treatments based on the same underlying technology, potentially expanding BriaCell's pipeline in a cost-effective manner. The company also suggests possible synergies with their existing cell-based cancer vaccine programs, which could enhance their overall therapeutic approach.
- TILsRx platform designed to overcome immune suppression and T cell exhaustion to activate tumor-infiltrating lymphocytes (TILs)
- Multivalent technology enables simultaneous engagement of multiple cancer-associated and immune pathway targets
- A preferred tolerability profile is expected due to selective cancer cell targeting within the tumor microenvironment (TME)
- TILsRx platform early agents include antibodies to B7-H3, an immune checkpoint found in several cancers including prostate, lung, breast, pancreatic, and ovarian
PHILADELPHIA and VANCOUVER, British Columbia, July 29, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ), (TSX: BCT) (“BriaCell”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, and its majority owned subsidiary, BriaPro Therapeutics Corp. (“BriaPro”), are pleased to announce that BriaPro is developing novel multivalent agents for cancer treatment. BriaPro has filed a provisional patent application for the underlying platform referred to as “TILsRx”.
The TILsRx platform enables simultaneous engagement of multiple tumor-associated and immune pathway targets. Multivalent agents (including antibodies, soluble receptors and cytokines) address immune suppression and T cell exhaustion often seen with tumor-infiltrating lymphocytes (TILs) and aim to improve T cell activation and persistence in the tumor microenvironment. Designed to activate TILs and enhance TIL binding to tumor cells as well as block immune checkpoints that suppress anti-tumor responses, TILsRx agents are multifunctional in their cancer killing actions. Specific elements in TILsRx agents include soluble CD80, which has a dual function as an immune checkpoint inhibitor and as an immunostimulator, anti-CD3, which is a potent T cell activator, IL-21, which is an enhancer of cytotoxic T cell function, and anti-STEAP1 (STEAP1 is a cancer antigen expressed in prostate cancer among others). An early candidate target is B7-H3, a tumor antigen which is overexpressed in prostate, lung, breast, pancreatic, and ovarian cancer while minimally expressed in normal tissue.
“We have developed novel multivalent anti-cancer agents which we expect to be both highly selective and highly effective, maximizing on-target efficacy while minimizing off-target toxicity to provide improved clinical responses in multiple indications,” stated Miguel Lopez-Lago, PhD, BriaCell and BriaPro CSO.
“The TILsRx platform reflects our goal to develop an effective and safe class of therapeutics for cancer patients. TILsRx agents combine shared core components that improve manufacturing efficiency with elements that target specific cell surface antigens. This strategy provides the flexibility to include new immunotherapy targets identified in the future. We look forward to advancing this exciting technology through pre-clinical and clinical stages,” stated Markus D. Lacher, PhD, a key inventor of the technology.
“Our advanced multivalent technology provides us with a platform to quickly expand our proprietary pipeline of novel immuno-oncology programs in BriaPro in a cost-effective manner,” stated Dr. William V. Williams, BriaPro and BriaCell President & CEO. “We anticipate that the multivalent approach will have activity against multiple types of cancers and may also synergize with BriaCell’s cell-based cancer vaccine programs.”
About BriaCell Therapeutics Corp.
BriaCell is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. More information is available at https://briacell.com/.
About BriaPro Therapeutics Corp.
BriaPro is a pre-clinical stage immunotherapy company developing binding agents and proteins with the intention to boost the ability of the body’s own cancer-fighting cells to destroy cancerous tumors.
Safe Harbor
This press release contains “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements, including those about the TILsRx platform providing a preferred tolerability profile due to its selective cancer cell targeting; the TILsRx platform's ability to be both highly selective and highly effective, maximizing on-target efficacy while minimizing off-target toxicity to provide improved clinical responses in multiple indications; BriaPro further advancing the TILsRx platform through pre-clinical and clinical stages; the TILsRx platform having activity against multiple types of cancers; and the TILsRx platform’s potential to synergize with BriaCell’s cell-based cancer vaccine programs, are based on BriaCell and BriaPro’s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully under the heading “Risks and Uncertainties” in BriaCell and BriaPro’s most recent Management’s Discussion and Analysis, under the heading “Risk Factors” in BriaCell’s most recent Annual Information Form, and under “Risks and Uncertainties” in: (i) BriaCell’s other filings with the Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission, and (ii) BriaPro’s other filings with the Canadian securities regulatory authorities, all of which are available under BriaCell and BriaPro’s profiles on SEDAR+ at www.sedarplus.ca and on BriaCell’s profile on EDGAR at www.sec.gov. Forward-looking statements contained in this announcement are made as of this date. BriaCell Therapeutics Corp. and BriaPro Therapeutics Corp. undertake no duty to update such information except as required under applicable law.
Neither the Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release.
Contact Information
BriaCell and BriaPro Contact:
William V. Williams, MD
President & CEO, BriaCell and BriaPro
1-888-485-6340
info@briacell.com
Investor Relations Contact:
investors@briacell.com
FAQ
What is BriaCell's new TILsRx platform and how does it work?
Which types of cancer does BCTX's new technology target?
What are the key components of BriaCell's TILsRx platform?
How does BCTX's new platform differ from existing cancer treatments?
What is the current development stage of BriaCell's TILsRx platform?
